CAREY OLSEN: Carey Olsen and Alter Domus advise Gyrus Capital on €600 million continuation fund

Press Release from Carey Olsen, Thursday 19 November, 2024.

Carey Olsen and Alter Domus have advised Geneva-based healthcare and sustainability investment firm Gyrus Capital (“Gyrus”) on the final close of its €600 million continuation fund led by AlpInvest, to support the continued growth of Essential Pharma.

Since Gyrus acquired Essential Pharma in 2019, the company has grown into a global, high growth specialty pharma group with significant development opportunities. With a focus on ensuring that patients have access to low volume, clinically differentiated pharmaceutical products, the additional capital will allow Essential Pharma to build on its diverse portfolio of established and rare disease medicines. 

CAREY OLSEN: Carey Olsen and Alter Domus advise Gyrus Capital on €600 million continuation fund

In addition to being led by AlpInvest, a subsidiary of Carlyle Global Investment Solutions, the continuation vehicle was supported by StepStone Group including other new and existing investors, as well as reinvestment from both Gyrus and management.

The Guernsey corporate team advising on the transaction comprised partner David Crosland, senior associates Colin Calvert, Sukhvinder Chana and James Cooke, associates Lisa Bailey and Claire Cooke, and trainee Tom Andrews. Alter Domus Guernsey has, alongside Carey Olsen, supported Gyrus since their Fund I launch, providing specialist fund administration solutions from their local office. The fund services team supporting Gyrus in this transaction included associate directors Matt Jackson and Sarah Lacey, senior manager Stuart Foster, managers Kyle Spruce and Mel Boscher, and senior associate Dan Guilbert.

David Crosland commented: “We are pleased to have worked alongside Alter Domus in advising long-standing client Gyrus on this significant transaction for both Gyrus and Essential Pharma, which will contribute to Essential Pharma’s next phase of growth as it delivers essential medicines for patients internationally and advances its expansion into rare diseases. The success of this transaction highlights how Guernsey continues to provide an ideal domicile for continuation funds in addition to Carey Olsen’s expertise as the leading legal adviser to the Guernsey investment funds sector.”

CAREY OLSEN: Carey Olsen and Alter Domus advise Gyrus Capital on €600 million continuation fund

Tom Amy, country executive of Alter Domus Guernsey, commented: “This transaction presented us with various challenges including the fund flow mechanics and volume of investors, which we navigated in close coordination with Gyrus, Carey Olsen and Weil as onshore counsel. I am immensely proud of dedication from so many colleagues and their expertise spanning fund administration, accounting, compliance and governance operations.”

13 March 2024

NETHERLANDS: Bangladesh-Netherlands sign deal to amend double tax avoidance agreement

Bangladesh on Tuesday signed a fresh agreement with the Netherlands to amend the existing double taxation avoidance and prevention of tax evasion agreement by making changes in some articles to widen

Read More
26 June 2025

EU: EU eyes higher fees on US, British tourists to repay post-Covid debts

British and American tourists could pay higher fees to enter the EU under a plan to boost the bloc’s tax revenues. The EU is considering taxing foreign travelers to pay back part of the €350 billion

Read More
19 July 2025

CAREY OLSEN: Carey Olsen advises Jupiter Research Capital on first USD denominated fund

Press Release from Carey Olsen, Friday 18 July, 2025. Carey Olsen has acted as Cayman Islands counsel to leading China-based asset management firm Jupiter Research Capital (Asia) Limited (“Jupiter

Read More
27 June 2025

SWITZERLAND: Swiss beneficial owner register to tackle money laundering

Switzerland will introduce a federal register to list the beneficial owners of shell companies to combat money laundering. The House of Representatives has backed a draft Bill that had been largely

Read More